Monoaminergic signatures of treatment-response heterogeneity in schizophrenia: a neuromelanin MRI study
Psychological Medicine · 2026 · 56
DOI: 10.1017/s0033291726106576 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychological Medicine, online erschienen am 09.11.2026. Verfasst von Fumihiko Ueno und 16 weiteren Autor:innen. Beteiligte Einrichtung: Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada. Hauptthemen laut MEDLINE: Melanins, Locus Coeruleus, Antipsychotic Agents, Schizophrenia. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brain and Behavior Research Foundation, Japan Agency for Medical Research and Development, CIHR.
Abstract (Originalsprache)
Background
Neuromelanin-sensitive MRI (NM-MRI) provides a noninvasive measure of signal within monoaminergic nuclei, including the substantia nigra/ventral tegmental area (SN–VTA) and locus coeruleus (LC). These signals are thought to reflect long-term monoaminergic-related processes. Although presynaptic dopamine dysfunction is implicated in schizophrenia, the contribution of monoaminergic-related NM-MRI signal alterations to treatment-response heterogeneity, including clozapine nonresponse, remains unclear.
Methods
We conducted a cross-sectional NM-MRI study, including patients with ultra-resistant schizophrenia (URS; n = 16), clozapine-responsive treatment-resistant schizophrenia (non-URS; n = 16), first-line antipsychotic responders (FLR; n = 20), and healthy controls (HCs; n = 26). NM-MRI contrast ratios (CR) were quantified in the SN–VTA and LC. Group differences were assessed using covariate-adjusted models, and voxel-wise analyses were performed to localize SN–VTA effects.
Results
SN–VTA CR was higher in both URS ( d = 1.01) and FLR ( d = 0.94) than in HCs, with voxel-wise analyses localizing these effects mainly to dorsal SN–VTA regions. In contrast, LC CR was higher in URS than in FLR ( d = 0.99), whereas URS did not differ significantly from HCs. NM-MRI signals were not associated with symptom severity or cognitive measures.
Conclusions
These findings support the view that schizophrenia treatment-response subgroups may differ in long-term monoaminergic-related (NM-MRI) signal patterns. Elevated NM-MRI signal within dopaminergic nuclei may characterize both antipsychotic-responsive and clozapine nonresponsive schizophrenia, whereas additional noradrenergic involvement may contribute to severe treatment resistance. NM-MRI may help characterize biologically meaningful heterogeneity within treatment-resistant schizophrenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada.
- Department of Mental Health, The Ottawa Hospital, Ottawa, Canada.
- Neuroscience Program, Ottawa Hospital Research Institute, Ottawa, Canada.
- Department of Psychiatry, University of Ottawa, Ottawa, Canada.
- Department of Psychiatry and Behavioral Health, Stony Brook University Renaissance School of Medicine, Stony Brook, USA.
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
ORCID-Profile: Fumihiko Ueno, Shinichiro Nakajima, Edgardo Torres-Carmona, Takahide Etani
Förderung
- Brain and Behavior Research Foundation
- Japan Agency for Medical Research and Development
- CIHR
- National Alliance for Research on Schizophrenia and Depression
- Canadian Institutes of Health Research
- Ontario Mental Health Foundation
Zitieren
APA
Ueno, F., Honda, S., Nakajima, S., Cassidy, C. M., Iwata, Y., Horga, G., Torres-Carmona, E., Song, J., Etani, T., Homma, S., Sekihara, S., Tsugawa, S., de Luca, V., Agarwal, S. M., Remington, G., Gerretsen, P., & Graff-Guerrero, A. (2026). Monoaminergic signatures of treatment-response heterogeneity in schizophrenia: a neuromelanin MRI study. Psychological Medicine, 56. https://doi.org/10.1017/s0033291726106576
Vancouver
Ueno F, Honda S, Nakajima S, Cassidy CM, Iwata Y, Horga G, et al. Monoaminergic signatures of treatment-response heterogeneity in schizophrenia: a neuromelanin MRI study. Psychological Medicine. 2026;56. doi:10.1017/s0033291726106576
BibTeX
@article{Ueno2026,
author = {Ueno, Fumihiko and Honda, Shiori and Nakajima, Shinichiro and Cassidy, Clifford M and Iwata, Yusuke and Horga, Guillermo and Torres-Carmona, Edgardo and Song, Jianmeng and Etani, Takahide and Homma, Saki and Sekihara, Shunya and Tsugawa, Sakiko and de Luca, Vincenzo and Agarwal, Sri Mahavir and Remington, Gary and Gerretsen, Philip and Graff-Guerrero, Ariel},
title = {Monoaminergic signatures of treatment-response heterogeneity in schizophrenia: a neuromelanin MRI study},
journal = {Psychological Medicine},
year = {2026},
volume = {56},
doi = {10.1017/s0033291726106576}
}
EUVIMED